[Our experience in the treatment of acute lymphoblastic leukemias (ALL) having different risk levels with the BFM-83 therapeutic protocol]. 1988

M Bernacer, and J Aracil, and T Contra, and C Gil, and J López, and B López-Ibor, and N Martín, and C Melero, and F Valverde, and C Vecilla
Fundación Jiménez Díaz, Servicio de Pediatría, Madrid.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002985 Clinical Protocols Precise and detailed plans for the study of a medical or biomedical problem and/or plans for a regimen of therapy. Protocols, Clinical,Research Protocols, Clinical,Treatment Protocols,Clinical Protocol,Clinical Research Protocol,Clinical Research Protocols,Protocol, Clinical,Protocol, Clinical Research,Protocols, Clinical Research,Protocols, Treatment,Research Protocol, Clinical,Treatment Protocol
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D054198 Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias. Leukemia, Lymphoblastic,Leukemia, Lymphoid, Acute,Lymphoblastic Leukemia,Lymphoblastic Lymphoma,Lymphocytic Leukemia, Acute,Lymphoma, Lymphoblastic,ALL, Childhood,Acute Lymphoid Leukemia,Leukemia, Acute Lymphoblastic,Leukemia, Lymphoblastic, Acute,Leukemia, Lymphoblastic, Acute, L1,Leukemia, Lymphoblastic, Acute, L2,Leukemia, Lymphoblastic, Acute, Philadelphia-Positive,Leukemia, Lymphocytic, Acute,Leukemia, Lymphocytic, Acute, L1,Leukemia, Lymphocytic, Acute, L2,Lymphoblastic Leukemia, Acute,Lymphoblastic Leukemia, Acute, Adult,Lymphoblastic Leukemia, Acute, Childhood,Lymphoblastic Leukemia, Acute, L1,Lymphoblastic Leukemia, Acute, L2,Lymphocytic Leukemia, L1,Lymphocytic Leukemia, L2,Acute Lymphoblastic Leukemia,Acute Lymphocytic Leukemia,Childhood ALL,L1 Lymphocytic Leukemia,L2 Lymphocytic Leukemia,Leukemia, Acute Lymphocytic,Leukemia, Acute Lymphoid,Leukemia, L1 Lymphocytic,Leukemia, L2 Lymphocytic,Lymphoid Leukemia, Acute,Precursor Cell Lymphoblastic Leukemia Lymphoma

Related Publications

M Bernacer, and J Aracil, and T Contra, and C Gil, and J López, and B López-Ibor, and N Martín, and C Melero, and F Valverde, and C Vecilla
April 2015, Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,
M Bernacer, and J Aracil, and T Contra, and C Gil, and J López, and B López-Ibor, and N Martín, and C Melero, and F Valverde, and C Vecilla
January 2005, Orvosi hetilap,
M Bernacer, and J Aracil, and T Contra, and C Gil, and J López, and B López-Ibor, and N Martín, and C Melero, and F Valverde, and C Vecilla
June 2014, Leukemia research,
M Bernacer, and J Aracil, and T Contra, and C Gil, and J López, and B López-Ibor, and N Martín, and C Melero, and F Valverde, and C Vecilla
January 1993, Medical and pediatric oncology,
M Bernacer, and J Aracil, and T Contra, and C Gil, and J López, and B López-Ibor, and N Martín, and C Melero, and F Valverde, and C Vecilla
January 1975, Godisen zbornik na Medicinskiot fakultet vo Skopje,
M Bernacer, and J Aracil, and T Contra, and C Gil, and J López, and B López-Ibor, and N Martín, and C Melero, and F Valverde, and C Vecilla
March 2012, Pediatric hematology and oncology,
M Bernacer, and J Aracil, and T Contra, and C Gil, and J López, and B López-Ibor, and N Martín, and C Melero, and F Valverde, and C Vecilla
September 2004, British journal of haematology,
M Bernacer, and J Aracil, and T Contra, and C Gil, and J López, and B López-Ibor, and N Martín, and C Melero, and F Valverde, and C Vecilla
January 1981, Sangre,
M Bernacer, and J Aracil, and T Contra, and C Gil, and J López, and B López-Ibor, and N Martín, and C Melero, and F Valverde, and C Vecilla
April 1999, Leukemia research,
M Bernacer, and J Aracil, and T Contra, and C Gil, and J López, and B López-Ibor, and N Martín, and C Melero, and F Valverde, and C Vecilla
January 1990, Haematology and blood transfusion,
Copied contents to your clipboard!